Display options
Cite
Patel SP, Othus M, Chae YK, et al. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020;26(10):2434doi: 10.1158/1078-0432.CCR-20-0790.
Patel, S. P., Othus, M., Chae, Y. K., Kurzrock, R. (2020). Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(10), 2434. https://doi.org/10.1158/1078-0432.CCR-20-0790
Patel, Sandip P, et al. "Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 26,10 (2020): 2434. doi: https://doi.org/10.1158/1078-0432.CCR-20-0790
Patel SP, Othus M, Chae YK, Kurzrock R. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020 May 15;26(10):2434. doi: 10.1158/1078-0432.CCR-20-0790. PMID: 32414761.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2020 May 15;26(10):2434. doi: 10.1158/1078-0432.CCR-20-0790.

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Sandip P Patel, Megan Othus, Young Kwang Chae, Razelle Kurzrock,

Affiliations

  1. UC San Diego Moores Cancer Center, La Jolla, California. [email protected].
  2. Fred Hutchinson Cancer Research Center, Seattle, Washington.
  3. Northwestern University Feinberg School of Medicine, Chicago, Illinois.

PMID: 32414761 DOI: 10.1158/1078-0432.CCR-20-0790

[No abstract available.]

Substances

MeSH terms

Publication Types

Grant support